Nektar Therapeutics reports results for the quarter ended June 30 - Earnings Summary

• Nektar Therapeutics NKTR.OQ reported a quarterly adjusted loss of $2.95​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-3.75. The mean expectation of eight analysts for the quarter was for a loss of $3.03 per share. Wall Street expected results to range from $-3.79 to $-2.19 per share.

• Revenue fell 52.4% to $11.18 million from a year ago; analysts expected $10.85 million.

• Nektar Therapeutics's reported EPS for the quarter was a loss of $2.95​.

• The company reported a quarterly loss of $41.59 million.

• Nektar Therapeutics shares had fallen by 13.1% this quarter and gained 60.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 4.3% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Nektar Therapeutics is $95.00, about 77.1% above its last closing price of $21.75

This summary was machine generated from LSEG data August 8 at 04:14 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)